{"id":"lenalidomide-low-dose-dex","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Neutropenia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Constipation"},{"rate":"10-20","effect":"Neuropathy"},{"rate":"20-30","effect":"Infection"},{"rate":"10-20","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide is an immunomodulatory agent that enhances T-cell and natural killer cell proliferation, increases IL-2 and IFN-γ production, and has direct anti-proliferative effects on myeloma cells. Low-dose dexamethasone is a corticosteroid that provides additional anti-inflammatory activity and enhances the cytotoxic effects of lenalidomide against malignant plasma cells. This combination is synergistic in multiple myeloma treatment.","oneSentence":"Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and anti-myeloma effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:39.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT01816971","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2013-01","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":76},{"nctId":"NCT01946477","phase":"PHASE2","title":"Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-05-29","conditions":"Multiple Myeloma","enrollment":186},{"nctId":"NCT04892264","phase":"PHASE1","title":"Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-06-03","conditions":"Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":5},{"nctId":"NCT00482261","phase":"PHASE2","title":"A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":150},{"nctId":"NCT03651128","phase":"PHASE3","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":381},{"nctId":"NCT01155583","phase":"PHASE1, PHASE2","title":"Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2010-06","conditions":"Refractory Multiple Myeloma","enrollment":45},{"nctId":"NCT00581919","phase":"PHASE2","title":"Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-02","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT01518465","phase":"PHASE2","title":"Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2012-01-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":13},{"nctId":"NCT01530594","phase":"PHASE3","title":"Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2009-01","conditions":"Multiple Myeloma","enrollment":440}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lenalidomide/Low dose Dex","genericName":"Lenalidomide/Low dose Dex","companyName":"King Faisal Specialist Hospital & Research Center","companyId":"king-faisal-specialist-hospital-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and anti-myeloma effects. Used for Multiple myeloma (newly diagnosed and relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}